Analyst Call of the Year: Collins Stewart on Encysive (ENCY)

Normally, Wall Street analysts get beat up in the media for their bad calls. So today we wanted to highlight an outstanding call by an analyst.

The stock: Encysive Pharmaceuticals Inc. (Nasdaq: ENCY).
The analyst: Andrew Fein at Collins Stewart

Yesterday, Fein upgraded Encysive to Buy. Today, the company announced a deal to be acquired by Pfizer (NYSE: PFE) for $2.35 per share, a huge premium to yesterday's $1.08 close. If you followed Fein's advice and bought the stock yesterday before the close you would be up over 100% today. Friday's close was $0.85, so if you bought yesterday morning, after the call, you would be up even more.

Fein was positive on Encysive's pulmonary hypertension drug THELIN in the EU and potential US approval. Pfizer saw the same thing and jumped at the chance to buy the entire company.

Great Call!

Some other pharmaceutical stocks Fein has Buy ratings on: Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH), United Therapeutics Corp. (Nasdaq: UTHR), Array BioPharma, Inc. (Nasdaq: ARRY), GTC Biotherapeutics, Inc. (Nasdaq: GTCB), OSI Pharmaceuticals Inc. (Nasdaq: OSIP), Tercica Inc. (Nasdaq: TRCA), Metabasis Therapeutics Inc. (Nasdaq: MBRX), Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), Rosetta Genomics, Ltd. (Nasdaq: ROSG), Insmed Incorporated (Nasdaq: INSM), Hana Biosciences Inc. (Nasdaq: HNAB), Allos Therapeutics, Inc. (Nasdaq: ALTH), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS).

You May Also Be Interested In

• J Capital Research cautious on Microchip: 'riding high on AI hype but looks weak'
• Wright: in the last 24 hours, 72 ships and 20 million barrels of oil have transited through the Strait of Hormuz
• Trump: Today’s Housing News Conference and Signing is hereby cancelled